News
![Executive Changes Hit NuVasive Hard](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Executive Changes Hit NuVasive Hard
Advances in medical science have had a dramatic impact on the quality of care that patients receive. In the area of spinal surgery, NuVasive (NASDAQ: NUVA) has made a lot of headway with its minimally
![Cerner Corporation Meets Expectations in Second Quarter With Solid Recurring Revenue](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Cerner Corporation Meets Expectations in Second Quarter With Solid Recurring Revenue
Cerner Corporation (NASDAQ: CERN) got off to a solid start in 2017 with its first-quarter results. The healthcare technology giant posted both revenue and earnings at the upper end of its guidance.On
![Cerner Corporation Meets Expectations in Second Quarter With Solid Recurring Revenue](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Cerner Corporation Meets Expectations in Second Quarter With Solid Recurring Revenue
Cerner Corporation (NASDAQ: CERN) got off to a solid start in 2017 with its first-quarter results. The healthcare technology giant posted both revenue and earnings at the upper end of its guidance.On
![Mighty AstraZeneca Takes a Lickin' on Failed Mystic Trial](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Mighty AstraZeneca Takes a Lickin' on Failed Mystic Trial
When AstraZeneca (NYSE: AZN) spurned overtures from Pfizer (NYSE: PFE) to combine in one of the biggest merger deals of all time, it told investors not to worry. It had plenty of irons in the fire
![Mighty AstraZeneca Takes a Lickin' on Failed Mystic Trial](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Mighty AstraZeneca Takes a Lickin' on Failed Mystic Trial
When AstraZeneca (NYSE: AZN) spurned overtures from Pfizer (NYSE: PFE) to combine in one of the biggest merger deals of all time, it told investors not to worry. It had plenty of irons in the fire
![Why Tetraphase Pharmaceuticals Fell 11.7% Today](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Why Tetraphase Pharmaceuticals Fell 11.7% Today
After reporting positive trial results for its lead product candidate on July 25, Tetraphase Pharmaceuticals (NASDAQ: TTPH) announced a $60 million share offering today that will dilute investors, and
![Baxter International Inc.'s Revenue Growth Snoozes, but Check Out the Earnings Growth](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Baxter International Inc.'s Revenue Growth Snoozes, but Check Out the Earnings Growth
Baxter (NYSE: BAX) kept with its trend in the second quarter of marginal revenue growth, but included a substantial improvement in spending, resulting in an increase in earnings that once again beat
![Natus Medical Inc Looks to Turn Things Around](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Natus Medical Inc Looks to Turn Things Around
Natus Medical (NASDAQ: BABY) continued the trend from the first quarter of the year: Revenue came in substantially higher in the second quarter, due to the addition of revenue from the company's
![Did the Checkpoint Inhibitor Bubble Just Burst?](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Did the Checkpoint Inhibitor Bubble Just Burst?
Shares of Agenus (NASDAQ: AGEN), a small-cap cancer immunotherapy company, were down by almost 16% at 1:20 p.m. Thursday as a result of AstraZeneca's (NYSE: AZN) Mystic trial missing its primary
![Did the Checkpoint Inhibitor Bubble Just Burst?](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Did the Checkpoint Inhibitor Bubble Just Burst?
Shares of Agenus (NASDAQ: AGEN), a small-cap cancer immunotherapy company, were down by almost 16% at 1:20 p.m. Thursday as a result of AstraZeneca's (NYSE: AZN) Mystic trial missing its primary
![Novavax, Inc.: Buy the Dip?](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Novavax, Inc.: Buy the Dip?
Novavax's (NASDAQ: NVAX) investors can't seem to catch a break. The clinical-stage vaccine maker has been down on its luck ever since it released disappointing phase 3 trial results last year for its
![Corning Exceeds Expectations on Optical and Gorilla Glass Strength](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Corning Exceeds Expectations on Optical and Gorilla Glass Strength
Corning Incorporated (NYSE: GLW) announced second-quarter 2017 results on Wednesday morning, easily beating expectations on both the top and bottom lines, thanks to strong showings from both its
![Corning Exceeds Expectations on Optical and Gorilla Glass Strength](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Corning Exceeds Expectations on Optical and Gorilla Glass Strength
Corning Incorporated (NYSE: GLW) announced second-quarter 2017 results on Wednesday morning, easily beating expectations on both the top and bottom lines, thanks to strong showings from both its
![Exact Sciences Continues to Surprise to the Upside](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Exact Sciences Continues to Surprise to the Upside
Exact Sciences (NASDAQ: EXAS) reported second-quarter financial results today that exceeded industry-watchers' forecasts, continuing a string of successes that has frustrated short-sellers and caused
![Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense
Gilead Sciences (NASDAQ: GILD) is nearing a crossroads of sorts. In short, AbbVie's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a
![Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense
Gilead Sciences (NASDAQ: GILD) is nearing a crossroads of sorts. In short, AbbVie's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a
![Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales
When Gilead Sciences, Inc. (NASDAQ: GILD) reported its first-quarter results earlier this year, everyone expected sales for the biotech's hepatitis C franchise to be way down. Those expectations were
![Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales
When Gilead Sciences, Inc. (NASDAQ: GILD) reported its first-quarter results earlier this year, everyone expected sales for the biotech's hepatitis C franchise to be way down. Those expectations were
![Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales
When Gilead Sciences, Inc. (NASDAQ: GILD) reported its first-quarter results earlier this year, everyone expected sales for the biotech's hepatitis C franchise to be way down. Those expectations were
![Biogen Inc Wants to Be the "Fastest-Growing Large-Cap Biotech Company"](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Biogen Inc Wants to Be the "Fastest-Growing Large-Cap Biotech Company"
Biogen (NASDAQ: BIIB) started the biotech earnings season off with a bang, generating enough revenue for the company to have confidence to increase its revenue guidance for the year. Earnings weren't
![The CEO Behind Lipitor Is Working on a Promising New Cholesterol Drug](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
The CEO Behind Lipitor Is Working on a Promising New Cholesterol Drug
Lipitor is one of the most commonly prescribed medicines on the planet, and one of the men behind it, Roger Newton, is currently working on a cheap and effective cholesterol-lowering drug.In this
![Why Amedisys Is Crashing 14.3% Today](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Why Amedisys Is Crashing 14.3% Today
After the Centers for Medicare and Medicaid Services (CMS) said it may reduce reimbursement for home healthcare by 0.4% in 2018, shares in Amedisys Inc. (NASDAQ: AMED) are losing 14.3% of their value
![BASTIDE : FINALISATION DE 5 ACQUISITIONS EN FRANCE ACCROISSEMENT DES PARTS DE MARCHE EN RESPIRATOIRE ET DEVELOPPEMENT DE LA VENTE EN LIGNE](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
BASTIDE : FINALISATION DE 5 ACQUISITIONS EN FRANCE ACCROISSEMENT DES PARTS DE MARCHE EN RESPIRATOIRE ET DEVELOPPEMENT DE LA VENTE EN LIGNE
Le Groupe Bastide Le Confort Médical annonce avoir finalisé 5 opérations de croissance externe en juillet en France, quatre dans le domaine des prestations de services en Assistance....
![Here's Why Tetraphase Pharmaceuticals Rose as Much as 26.8% Today](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Here's Why Tetraphase Pharmaceuticals Rose as Much as 26.8% Today
Shares of clinical-stage biopharma Tetraphase Pharmaceuticals (NASDAQ: TTPH) soared nearly 27% today after the company announced positive top-line results for a phase 3 trial evaluating its lead
![Here's Why Integra LifeSciences Holdings Corp. Is Sinking Today](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Here's Why Integra LifeSciences Holdings Corp. Is Sinking Today
Shares of Integra LifeSciences (NASDAQ: IART), a medical device company that focuses on surgical products, fell as much as 11% in early morning trading on Wednesday after the release of second-quarter